(Q36407379)

English

Sorafenib

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

Sorafenib. (English)

1 reference

Europe PubMed Central

14 August 2017

author name string

Brian I Rini

1

1 reference

Europe PubMed Central

14 August 2017

language of work or name

0 references

publication date

1 March 2006

1 reference

Europe PubMed Central

14 August 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

14 August 2017

7

1 reference

Europe PubMed Central

14 August 2017

4

1 reference

Europe PubMed Central

14 August 2017

453-461

1 reference

Europe PubMed Central

14 August 2017

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

The biology of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Raf: a strategic target for therapeutic development against cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

BAY 43-9006: preclinical data

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Discovery of a novel Raf kinase inhibitor

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.453

21 January 2018

Identifiers

10.1517/14656566.7.4.453

1 reference

Europe PubMed Central

14 August 2017

release_thsf5qaehbdsdhfg4h2h2t5ocm

1 reference

https://api.fatcat.wiki/v0/release/thsf5qaehbdsdhfg4h2h2t5ocm

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36407379&oldid=1838781387"